Thanks Bobby, but as it says in that page techniques are still in their infancy, so the government and Devolved Administration partners are working closely with academics, UK Research and Innovation and the Natural Environment Research Council and water companies in developing and testing this cutting-edge approach. We are working with many UK universities and are part of a number of projects in this. We are further along with China provinces with options to include AI as part of their detection plan for equipment being shipped later this year. If we are all really honest, the UK is way behind other countries.
Shandy, the exceptionals are one off. In May there was a number of disposals, an acquisition, legal settlements from closing and disposing of non-performing assets.
EBITDA loss is actually 7% lower than previous year. Additional administration costs are associated with increased personnel and growth in revenues per client after acquisition, additional facilities for AI hub and increased sales personnel and new science team members of Labskin to accommodate the increased demand.
@SeanT that dry cough was after wolfing down a McDonalds before the interview and nt enough to drink :)
The reason I make this point is that on Page 11 of the Annual Report (signed off on the 12th of June) is that it states specifically:
"The Directors have prepared cash flow projections to determine funding requirements of the Group. After making enquiries, the Directors have a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt a going concern basis in preparing the annual report and consolidated financial statements."
@shandypants I respect your right to such an opinion but that statement is perhaps disingenuous and unfair.
Cash at any point in time, for any business, does not reflect the true state of the underlying business, which normally includes trade debtors or debt facilities available to the Company. The fact is, that management, via Cellulac, provided a low-interest unsecured loan was to keep high-value developments on fast track, without putting any pressure on day to day working capital.
I had previously mentioned that we had access to debt as growth has been strong. The additional investments in the Post-Year-End highlights of the Annual Report were taken from Working Capital. The flexible loan facility, which is not currently needed, provides a cushion if needed to keep expanding.
If there was an issue on working capital or a going concern, the auditors would have highlighted this in their Auditor's report in the Annual Report signed off last week.
There will be a 3-Pin plug for UK use ??
We will be testing this over the next couple of months in our CL3 laboratory. It has been accelerated as stated in a recent RNS in collaboration with Modern Water equipment.
Work in Progress and we will update as we hit Milestones over next weeks and months.
The Sars-CoV-2 pipe is multi-step.
Labskin is testing the virus on surface of skin for sanitisers
Labskin is testing soft tissue (mimicking nasal mucosa) will be testing mouthwash ingredients to verify killing of the virus to reduce, or eliminate, dispersal in dental treatment via aerosol in drilling and dental hygiene/cleaning
Next is the health and safety element of exposure to the virus in various designs of the disposable pathogenic virus detection system.
AI integrated with miniaturisation of detection system wi ll have to be tested with a variety of pathogens, one of which happens to be the COVID19 virus.
Labskin team have increased in size now the lab has been enlarged and 100% social distance compliant. Now production ready for Modern Water reagent. And all the above is on top of normal Labskin skincare which was growing before COVID19 and conference season being virtual back to normal
@K3VMC In a COVID19 world, I am pleased that we have been able to provide the opportunity for you to secure your profits. No doubt you will continue to keep a watchful eye on our progress and when the time comes jump back on board. The very best to you and yours.
Actually now that you mention this, I feel it necessary to make this point.
Having worked with TPI since March 2019 I have found them to be nothing but 100% supportive to Integumen and Modern Water. They introduced me to Modern Water before Christmas and when I expressed an interest in MW's distribution channel, were instrumental in helping manage a very needed funding round, for which they took their fees in warrants. Meaning that they end up having to pay for the shares (at 0.5p) for the privilege of getting paid for helping to begin the turnaround.
The share price has recovered and like everyone who participated in the placing, and investors who bought when the share price dropped below the placing price in March 2020, they paid for and exercised warrants of 22.5m and were entitled to dispose, pay their CGT and bank their profits, like every other investor. I have been informed that they have sold sufficient amount to leave them with enough below the 3% threshold and believing them to remain supportive I have no reason to expect otherwise that they hold and remain a long term supportive shareholder.
Like every shareholder, they have a right to sell should they wish to do so, but it is disingenuous speculate that they would do so in small lots. They are the company broker with a responsibility to maintain an orderly market and be supportive in the company's growth.
I am grateful to all supportive shareholders, which is why I maintain an open communication with ALL shareholders, so long as you respect that I must do so within AIM and EU MAR Rules.
I am not sure if shareholders grasped the implications of the slide on Virtual Clinical Trials 2021 and a solution for COVID19 restricted patients who must remain shielded in their home, Nursing Homes.
Effectively this enables skin disease clinical trials to be carried out with social distance rules by remotely capturing the Microbiome of a human volunteers' skin in their home under the supervision of a HD video remote supervisor, instantly freeze the swab, and ship to Labskin laboratories where the human volunteers' skin microbiome (surface) is cloned. The human volunteer/patient's cloned skin is then tested in Labskin laboratory, without the patient having to leave their home, if collected by a courier.
The Labskin team presented at the Microbiome Connect conference yesterday and details (including the ability to download the presentation slide deck - and detail notes) can be found here. https://www.labskin.co.uk/labskin-at-microbiome-connect-skin-2020/ Small additional information on the COVID-19 CL3 laboratory at the end of the Slide Deck that can be downloaded from this link
Mature, or PrematureToday 20:37
Hi All
It may appear that we are not out there promoting the heck out of what we have been working on for 4 years (yes, 4 years). Wastewater based epidemiology (study of epidemics in sewage) has been around for decades.
COVID19 has been around for 7 months. At the last count there were 115 vaccine targets, lots of test-kit manufacturers and 10's of therapies to treat the disease out there trying around the clock to deliver the silver bullet.
We are fortunate that we have a 4 year head start to deliver an instant alert system when hundreds of PhD and under graduates are jumping down manholes taking samples and running back to their labs to use a gene sequencing protocol.
We just got the keys to the CL3 laboratory, having taken 8 weeks looking and 5 weeks passing all the qualifications to work on SARS-CoV-2 in this secure facility on health, safety issues for both our Labskin and how we deal with disposable virus in the real world when we do roll out the RAWTest units.
It takes, and will take weeks to get through all this before we can even test this in the field. We will get lots right and somethings wrong, but we have to get them right in the secure lab, not expose any user in the field.
So PR and IR around this is building. There are plenty of the right people who know what we are doing and once it's done, it will be the right time to let the world knkw it is ready.
So long term investors, supporters, researchers will have been following what we are doing and building out to deliver. Others may be frustrated, but all the pieces are put in place. Our collaboration with Modern Water and their existing trusted network of installed Microtox units. The clients who have used them for 30 years around the world. ecowaterOS consortium who are involved in miniaturising it, universities who have been testing it, OEM producers who can scale it to mass production level on multiple continents and clients who know they need it.
It is easy to get it in the papers, it is better to get it into production for a market that has, and is building pent up demand for instant detection and identification of pathogenic bacteria and viruses for the long term, when long after COVID19, wastewater based epidemiology will still be an important are for us, when all the vaccine chasers are gone
All the above is in the public domain. There is nothing material in what is stated above, that is not in our RNS over the last two or three months
Hi All
It may appear that we are not out there promoting the heck out of what we have been working on for 4 years (yes, 4 years). Wastewater based epidemiology (study of epidemics in sewage) has been around for decades.
COVID19 has been around for 7 months. At the last count there were 115 vaccine targets, lots of test-kit manufacturers and 10's of therapies to treat the disease out there trying around the clock to deliver the silver bullet.
We are fortunate that we have a 4 year head start to deliver an instant alert system when hundreds of PhD and under graduates are jumping down manholes taking samples and running back to their labs to use a gene sequencing protocol.
We just got the keys to the CL3 laboratory, having taken 8 weeks looking and 5 weeks passing all the qualifications to work on SARS-CoV-2 in this secure facility on health, safety issues for both our Labskin and how we deal with disposable virus in the real world when we do roll out the RAWTest units.
It takes, and will take weeks to get through all this before we can even test this in the field. We will get lots right and somethings wrong, but we have to get them right in the secure lab, not expose any user in the field.
So PR and IR around this is building. There are plenty of the right people who know what we are doing and once it's done, it will be the right time to let the world knkw it is ready.
So long term investors, supporters, researchers will have been following what we are doing and building out to deliver. Others may be frustrated, but all the pieces are put in place. Our collaboration with Modern Water and their existing trusted network of installed Microtox units. The clients who have used them for 30 years around the world. ecowaterOS consortium who are involved in miniaturising it, universities who have been testing it, OEM producers who can scale it to mass production level on multiple continents and clients who know they need it.
It is easy to get it in the papers, it is better to get it into production for a market that has, and is building pent up demand for instant detection and identification of pathogenic bacteria and viruses for the long term, when long after COVID19, wastewater based epidemiology will still be an important are for us, when all the vaccine chasers are gone
All the above is in the public domain. There is nothing material in what is stated above, that is not in our RNS over the last two or three months
We would inform the market if there was a delay beyond normal 6 months.
Sorry Mr Trotter My Bad, just not enough characters in the tweet to fit it all in. Just thought it important to point out that this is not going to go away. I seen on CNN that (hopefully) if Modern vaccine works that 100m will be available in 2021 in US.
The world needs at least 2 billion. The largest producer now of vaccines is Merck and it currently produces 150m flu vaccines a year, and that requirement will not go away either. Surveillance and hot-spot detections are going to be the normal in the post pandemic period, even just to maintain then R0 below 1 to avoid the spread. That is the only way we can keep the waves low until we are all immune, or until the next epidemic/pandemic
An overnight success tends to take more than a few months. Compound growth generates compound wealth. Patience is the key.
This company has had a complete change of business model and a new Board.
Year-end accounts and AIM Rule 19: An AIM company must publish annual audited accounts which must be sent to its shareholders without delay and in any event not later than six months after the end of the financial year to which they relate.
On the 6 April 2020 The FCA provided for extending deadlines to publishing accounts https://www.fca.org.uk/firms/extending-deadlines-publishing-fund-reports-and-accounts. This was due to the fact that many audit firms had their staff on lock-down over the last 10 weeks, or even furlough. Many audit company site visits were not possible so workarounds for virtual stock counts etc., had to be managed.
@somersetgreen There are many infectious diseases and you touch on just two - Norovirus and SARS-CoV-2, but up to 150 viruses can exist in Blackwater (waste from toilets that contain pathogens). Depending on the position of the detection unit a cruise ship may be able to identify a deck, a row of cabins or a column, assuming each floor includes the toilets in a stack from lower to higher deck.
As for identification, each pathogen binding agent is very specific to the target. The units will be single (1 target) detection or multiple as an in-line series of 4 for up to 4 pathogenic targets. If an alert is triggered, the crew doctor will be able to isolate the hotspot and individually test passenger cabin occupants before it spreads and isolate accordingly.
Once the detection occurs it will be necessary to replace the optical glass unit in the cartridge. It is not possible to insert an image here but you can see what I mean from the 3D animation and the image of the optical glass with the binding agent attached. here
https://twitter.com/gjbrandon/status/1267447643619364864?s=20
https://twitter.com/gjbrandon/status/1266014306329669635?s=20
Modern Water a a well established brand, recognised the world over, for their Microtox water contamination testing platform. It is a perfect distribution channel to which the Rinocloud AI real-time identification system can be dropped into. As it says in the RNS's we are collaborating and Modern Water equipment can be retrofitted with the Rinocloud system. However, this is a stand-alone unit and can be integrated into any wastewater monitoring system, with anybody. There is no exclusivity, it just suits both companies in a revenue shared sales, marketing and distribution channel.
We are not in the business of converting poop to potable water, but we can confirm if the output is safe enough to use with Microtox from MWG and confirm that no pathogenic microorganism is in the water.
Our IP is strong on many levels for both companies as can be seen from searches